Cefepime is increasingly used as empiric treatment for fever in the setting of neutropenia. We present a patient with acuteon-chronic renal disease who received cefepime at the appropriate dose for his glomerular filtration rate but developed cefepime-associated encephalopathy. Here, we review neurologic toxicities of cefepime and present suggestions for work-up and management.
INTRODUCTION
Fever in the setting of neutropenia is a frequent complication in pediatric and young adult patients who are undergoing chemotherapy. Although the etiology of the fever may not be infectious, these patients are routinely treated with empiric broad-spectrum antibiotics while blood cultures are pending to prevent life-threatening sepsis. An increasingly frequent choice for such empiric antibiotic therapy in patients with neutropenic cancer with fever is cefepime, a fourth-generation cephalosporin [1] [2] [3] [4] [5] [6] [7] . A rarely recognized adverse effect of cefepime is significant neurotoxicity, particularly in patients with renal impairment. These patients are at increased risk, because hepatic metabolism of cefepime is minimal, and 85% of each dose is excreted in the urine unchanged [8] . We present here the case of a patient with acute-on-chronic renal disease who received renally dose-adjusted cefepime as empiric treatment for fever in the setting of neutropenia and consequently developed significant neurologic toxicity that was attributed to cefepime. We also review the literature and discuss our recommendations for the management of patients who develop this severe complication.
PATIENT PRESENTATION
Our patient was an 18-year-old boy with a history of very-highrisk pre-B-cell acute lymphoblastic leukemia in his second complete remission after an isolated central nervous system (CNS) relapse 32 months after his original diagnosis. His most recent lumbar puncture had been performed 2 days before presentation, during which he received intrathecal methotrexate, cytarabine, and hydrocortisone. It is notable that, since his initial leukemia diagnosis, he had received frequent administration of intrathecal chemotherapy without any neurologic complications. In addition, the patient had completed craniospinal radiation therapy almost 2 months before presentation. The patient had a solitary left kidney and stage III chronic kidney disease secondary to chemotherapy and prolonged liposomal amphotericin therapy for a history of disseminated fungal infection. He was on several home oral medications, but none had been initiated recently or associated with neurotoxicity.
The patient was admitted to the hospital for fever in the setting of chemotherapy-induced pancytopenia and was noted on admission to have acute-on-chronic kidney injury. Although his baseline creatinine level was approximately 1 mg/ dL, it had risen to 1.65 mg/dL on the day of admission, which resulted in an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m 2 according to the Chronic Kidney Disease Epidemiology Collaboration equation [9] . However, because of the patient's baseline severely decreased muscle mass, his estimated GFR based on his serum creatinine level overestimated his renal function. The patient was started on empiric antibiotic treatment at admission with vancomycin, dosed by troughs, and cefepime (2 g every 12 hours). The cefepime dose was chosen to be appropriate for the patient's measured GFR of 35 mL/min/1.73 m 2 and his high infectious-risk status based on standardized guidelines [8] . The patient's GFR had been measured most recently 3 months before admission by the multiple-blood-sample method after intravenous injection of a nuclear tracer.
On day 5 of cefepime therapy, the patient was noted to be increasingly confused, tachycardic, and tachypneic despite being afebrile. Over an approximately 24-hour period, he developed intermittent fecal incontinence, excessive fatigue, and significantly decreased interaction and alertness and eventually became difficult to arouse. As a consequence, he was transferred to the intensive care unit for close neurologic observation. A rush computed tomography scan of the head was obtained to assess the patient for an intracranial hemorrhage, given his chemotherapy-induced thrombocytopenia; however, no acute changes were identified. An electroencephalogram revealed diffuse slowing and no occipital dominant rhythm, although no seizure activity was noted.
The next day (day 6 of cefepime therapy), results of magnetic resonance imaging of the patient's brain were negative for signs of methotrexate toxicity or other possible etiologies of his acute mental status change. To rule out a CNS infection or a recurrence of CNS leukemia, a lumbar puncture was performed; however, his cerebrospinal fluid (CSF) red and white blood cell counts were both 0, and no blasts or cytologic atypia were identified. His CSF glucose concentration, 63 mg/dL, was within the reference range, but his CSF protein level, 112 mg/ dL, was elevated. In addition, the results of testing of his CSF were negative for herpes simplex virus by polymerase chain reaction testing and negative for bacterial growth on culture. The patient stopped speaking and became combative, although he intermittently made purposeful movements and followed simple commands.
The pediatric neurology team was consulted and recommended discontinuing cefepime therapy, given reports of drug-induced neurotoxicity. Gram-negative bacterial coverage was subsequently transitioned from cefepime to ceftazidime. After the discontinuation of cefepime, our patient's mental status quickly returned to his baseline over the next 3 days, and his creatinine level also improved to 1.09 mg/dL with hydration. Given the rapid improvement in his mental status with the discontinuation of cefepime and lack of available testing, no drug levels were obtained. It should be noted that no infectious etiology for his fevers was identified. The patient was continued on ceftazidime therapy until his chemotherapy-induced neutropenia began to improve. No recurrence of his neurologic symptoms had been noted up to 12 months after his original presentation, even with continued intrathecal administration of methotrexate, cytarabine, and hydrocortisone chemotherapy.
DISCUSSION
Cefepime is administered frequently to immunosuppressed or neutropenic patients with fever of unknown etiology [2] [3] [4] [5] [6] [7] . In patients without impaired renal function, the half-life of the drug is 2 to 2.2 hours. Cefepime is 80% to 85% renally cleared as unmetabolized parent drug [1, 4, 6, 8, 10] . In patients with acute or chronic renal failure, cefepime accumulates in the CNS because of increased circulating unbound drug (decreased drug-serum protein binding), build-up of organic acids that competitively inhibit the drug's active transport, and dysfunction and increased penetration of the blood-brain barrier [1-3, 7, 10, 11] . Standardized recommendations of cefepime dose adjustment for various rates of creatinine clearance, either estimated with the Cockcroft-Gault formula or measured, have been established [8] . We hypothesize that our patient's acute renal failure rapidly decreased his true creatinine clearance rate. As a consequence, instead of administering 2 g of cefepime every 12 hours, as dosed appropriately according to his most recent GFR measurement, he should have been given 2 g of cefepime only once per day, which is a dose appropriate for a patient with a creatinine clearance rate between 11 and 29 mL/ min.
Although the adverse neurologic effects of cefepime are rare, severe drug-induced neurotoxicity has been recurrently reported, most frequently in patients with either acute or chronic renal failure. Symptoms include confusion, myoclonus, somnolence, coma, encephalopathy (1%), and seizures (0.1%). The onset of neurologic symptoms has ranged from 1 day to 1 month after the initiation of cefepime therapy [1, 3-7, 10, 11] . These neurotoxic effects of cefepime are directly secondary to high serum drug concentrations. A 2010 study in 30 febrile patients with neutropenia found a 50% probability of neurotoxicity in patients with plasma cefepime trough concentrations of ≥22 mg/L [3, 12] . Published 90% minimum inhibitory concentrations (MIC 90 s) of cefepime for the most common bacterial organisms that cause febrile neutropenia are significantly lower than this toxic range (6 mg/L for oxacillin-susceptible Staphylococcus aureus, 3 mg/L for oxacillin-susceptible coagulase-negative Staphylococcus and Viridans group Streptococci, 2 mg/L for Streptococcus pneumonia, ≤0.5 mg/L for Escherichia coli and Klebsiella pneumonia, and 8 mg/L for Pseudomonas aeruginosa), and the time the cefepime plasma concentration is above the MIC is the key determinant of cefepime's antimicrobial efficacy [12] [13] [14] . Cephalosporin-induced seizures are presumed secondary to the drugs' antagonistic effects on γ-aminobutyric acid (GABA) A receptors, which decrease the normal GABA-mediated inhibitory response and decrease the seizure threshold [1-3, 5-7, 10, 15] .
On the basis of our review of the literature and clinical experience, patients who develop altered mental status without medical explanation while receiving cefepime should have the drug discontinued if possible while further work-up for an etiology is performed, including measurement of cefepime serum levels, if available. Clinical high-pressure liquid chromatography measurements of cefepime plasma concentrations are becoming more available in tertiary care centers [16] . We recommend obtaining an electroencephalogram to assess for nonconvulsive status epilepticus or additional changes associated with cefepime-induced encephalopathy, which include loss of background activity, triphasic waves, slow rhythms in the δ and θ ranges, and multifocal sharp waves [1, 4, 10, 11] . Cefepime-associated seizure activity can be controlled effectively with benzodiazepine therapy, given the GABA-mediated etiology of convulsions [3] . Hemodialysis should be considered a treatment option in patients with severe encephalopathy to rapidly decrease the blood and CSF cefepime levels and shorten the duration of CNS toxicity, because 70% of a given dose of cefepime can be removed with a 3-hour session [3, 10] .
CONCLUSION
It is important to note that although cefepime-associated neurologic toxicity can frequently be prevented by dose-adjusting the medication for decreased renal function in patients with acute or chronic renal impairment, toxicity can still occur, as was the case in our patient. As a consequence, in patients with moderate-to-severe acute and/or chronic renal dysfunction, we recommend extreme caution in the use of cefepime for empiric Gram-negative coverage. In addition, we advise consideration of cefepime-induced neurotoxicity in the setting of acutely altered mental status and possible replacement of cefepime therapy with another antibiotic with broad-spectrum Gram-negative coverage, such as piperacillin-tazobactam or ceftazidime. Finally, in the event of mental status changes in a patient that are possibly attributable to cefepime therapy, measuring the cefepime serum drug levels can support this diagnosis of exclusion.
